PPAR-γ receptor ligands: novel therapy for pituitary adenomas
J. Clin. Invest. Anthony P. Heaney, et al. 111:1381 doi:10.1172/JCI16575 [Go to this article.]

Figure 6
Rosiglitazone treatment inhibits pituitary gonadotroph tumor growth and suppresses LH hormone levels in vivo (n = 5). Mice were inoculated subcutaneously with either LβT2 LH-secreting (a–d) or αT3 (e and f) gonadotroph pituitary tumor cells (∼200,000), and animals were randomized to receive either oral rosiglitazone (LβT2 cells, 5, 20, and 150 mg/kg/d; αT3 cells, 50 mg/kg/d) or vehicle. Representative photograph of tumors (a and e), tumor weights (b, d, and f), and serum LH (c) levels in LβT2 or αT3 gonadotroph tumor–bearing mice after 4 weeks of treatment with vehicle or rosiglitazone. There were five animals in each group. *P = 0.0002, **P = 0.004, ***P = 0.002, ^#P = 0.04 vs. vehicle.